

Title (en)
PGDH INHIBITORS AND METHODS OF MAKING AND USING

Title (de)
PGDH-INHIBITOREN UND VERFAHREN ZUM HERSTELLEN UND VERWENDEN

Title (fr)
INHIBITEURS PGDH ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

Publication
EP 4093385 A4 20240207 (EN)

Application
EP 21744496 A 20210122

Priority

- US 202062965062 P 20200123
- US 202063007755 P 20200409
- US 202063029184 P 20200522
- US 202063092116 P 20201015
- US 202063110803 P 20201106
- US 202163133965 P 20210105
- US 2021014783 W 20210122

Abstract (en)
[origin: WO2021151014A1] Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.

IPC 8 full level
A61K 31/085 (2006.01); **A61K 31/4453** (2006.01); **C07D 211/14** (2006.01)

CPC (source: EP IL KR US)
A61K 31/4184 (2013.01 - EP IL); **A61K 31/437** (2013.01 - EP IL); **A61K 31/4453** (2013.01 - EP IL KR); **A61K 31/454** (2013.01 - EP IL KR); **A61K 31/4545** (2013.01 - EP IL KR); **A61K 31/4709** (2013.01 - KR); **A61K 31/497** (2013.01 - KR); **A61K 31/506** (2013.01 - KR); **A61K 31/538** (2013.01 - KR); **A61K 31/5415** (2013.01 - KR); **A61P 17/00** (2018.01 - KR); **A61P 17/14** (2018.01 - KR); **C07D 211/14** (2013.01 - KR); **C07D 211/38** (2013.01 - EP IL); **C07D 235/06** (2013.01 - EP IL KR); **C07D 235/16** (2013.01 - EP IL KR); **C07D 249/18** (2013.01 - EP IL); **C07D 295/192** (2013.01 - EP IL); **C07D 401/06** (2013.01 - EP IL KR); **C07D 401/12** (2013.01 - KR); **C07D 401/14** (2013.01 - KR); **C07D 403/06** (2013.01 - EP IL KR); **C07D 405/14** (2013.01 - KR); **C07D 413/04** (2013.01 - EP IL); **C07D 413/06** (2013.01 - KR); **C07D 413/14** (2013.01 - EP IL KR); **C07D 417/04** (2013.01 - KR); **C07D 417/12** (2013.01 - KR); **C07D 471/04** (2013.01 - EP IL KR US); **C07D 487/04** (2013.01 - EP IL); **C07D 498/04** (2013.01 - KR); **C07D 519/00** (2013.01 - EP IL US)

Citation (search report)
[IA] DAMIEN Y. DUVEAU ET AL: "Structure-activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 2, 2014, Amsterdam NL, pages 630 - 635, XP055348274, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.11.081

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2021151014 A1 20210729; AU 2021211732 A1 20220825; CA 3168494 A1 20210729; CN 115335043 A 20221111; EP 4093385 A1 20221130; EP 4093385 A4 20240207; IL 294881 A 20220901; JP 2023511084 A 20230316; KR 20220146458 A 20221101; MX 2022009116 A 20221021; US 11345702 B1 20220531; US 11891389 B2 20240206; US 2022267325 A1 20220825

DOCDB simple family (application)
US 2021014783 W 20210122; AU 2021211732 A 20210122; CA 3168494 A 20210122; CN 202180024179 A 20210122; EP 21744496 A 20210122; IL 29488122 A 20220719; JP 2022543489 A 20210122; KR 20227028775 A 20210122; MX 2022009116 A 20210122; US 202117484398 A 20210924; US 202217725220 A 20220420